Shares of Merus NV (NASDAQ:MRUS) have been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $19.00.
Several analysts have recently commented on MRUS shares. Royal Bank of Canada lowered shares of Merus from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $21.00 to $16.00 in a research report on Wednesday, May 27th. HC Wainwright assumed coverage on shares of Merus in a research report on Friday, June 26th. They set a “buy” rating and a $23.00 target price on the stock. Guggenheim decreased their target price on shares of Merus from $26.00 to $23.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. BidaskClub upgraded shares of Merus from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Zacks Investment Research upgraded shares of Merus from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, March 18th.
In related news, major shareholder Bvf Partners L. P/Il purchased 1,462,510 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were bought at an average price of $14.00 per share, for a total transaction of $20,475,140.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bvf Partners L. P/Il purchased 87,254 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was bought at an average price of $15.20 per share, for a total transaction of $1,326,260.80. The disclosure for this purchase can be found here. 7.40% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in MRUS. Federated Hermes Inc. increased its position in shares of Merus by 68.2% in the first quarter. Federated Hermes Inc. now owns 1,812,000 shares of the biotechnology company’s stock valued at $21,925,000 after buying an additional 734,605 shares in the last quarter. Global Retirement Partners LLC increased its position in shares of Merus by 62.7% during the first quarter. Global Retirement Partners LLC now owns 2,603 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 1,003 shares in the last quarter. Platinum Investment Management Ltd. increased its position in shares of Merus by 22.3% during the fourth quarter. Platinum Investment Management Ltd. now owns 170,112 shares of the biotechnology company’s stock worth $2,395,000 after purchasing an additional 31,012 shares in the last quarter. EcoR1 Capital LLC increased its position in shares of Merus by 937.6% during the fourth quarter. EcoR1 Capital LLC now owns 1,718,200 shares of the biotechnology company’s stock worth $24,192,000 after purchasing an additional 1,552,600 shares in the last quarter. Finally, Driehaus Capital Management LLC increased its position in shares of Merus by 130.4% during the fourth quarter. Driehaus Capital Management LLC now owns 1,434,282 shares of the biotechnology company’s stock worth $20,195,000 after purchasing an additional 811,872 shares in the last quarter. Institutional investors own 62.02% of the company’s stock.
Shares of MRUS stock traded up $0.02 during trading hours on Thursday, hitting $15.49. The company’s stock had a trading volume of 239 shares, compared to its average volume of 96,998. The business has a fifty day moving average of $15.20 and a 200-day moving average of $15.26. The stock has a market cap of $459.44 million, a price-to-earnings ratio of -5.94 and a beta of 0.77. Merus has a twelve month low of $10.19 and a twelve month high of $20.95.
Merus (NASDAQ:MRUS) last released its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.14). The business had revenue of $6.30 million during the quarter, compared to analyst estimates of $8.05 million. Merus had a negative net margin of 225.21% and a negative return on equity of 62.96%. On average, analysts anticipate that Merus will post -2.29 earnings per share for the current fiscal year.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Featured Article: What does an inverted yield curve signify?
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.